Semaglutide, central retinal thickness and continuous glucose monitoring in persons with type 2 diabetes: A post-hoc analysis from a randomised trial
Open Access
- 10 April 2025
- journal article
- research article
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 39 (6) , 109039
Abstract
No abstract availableKeywords
Funding Information
- Health Research Foundation of Central Denmark Region (A3192)
- Danish Medical Association (2019-3780/41)
- Novo Nordisk Foundation (NNF170C0029064)
This publication has 33 references indexed in Scilit:
- Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed SemaglutideJAMA Ophthalmology, 2024
- Risk of diabetic retinopathy and diabetic macular oedema with sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated databaseDiabetologia, 2024
- Continuous glucose monitoring in adults with type 2 diabetes: a systematic review and meta-analysisDiabetologia, 2024
- Effects of semaglutide and empagliflozin on oxygenation, vascular autoregulation, and central thickness of the retina in people with type 2 diabetes: A prespecified secondary analysis of a randomised clinical trialJournal of Diabetes and its Complications, 2023
- Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trialDiabetologia, 2023
- Early Worsening of Retinopathy in Type 1 and Type 2 Diabetes After Rapid Improvement in Glycaemic Control: A Systematic ReviewDiabetes Therapy, 2021
- Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045Ophthalmology, 2021
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialThe Lancet, 2019
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trialThe Lancet, 2018
- Diabetic retinopathyThe Lancet, 2010